NCT00762021

Brief Summary

To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof SN60AT lens or the AcrySof SN60WF lens.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2006

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

September 26, 2008

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 30, 2008

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2009

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

December 22, 2010

Completed
Last Updated

December 22, 2010

Status Verified

November 1, 2010

Enrollment Period

2.7 years

First QC Date

September 26, 2008

Results QC Date

September 30, 2010

Last Update Submit

November 24, 2010

Conditions

Keywords

cataract

Outcome Measures

Primary Outcomes (3)

  • Posterior Capsule Opacification (PCO)

    Thickening and opacification of the transparent membrane on which the intraocular lens is placed assessed by taking a digital retroillumination image of each eye with a dedicated retroillumination camera system. The photographs were analyzed with POCO software to measure the percentage area of PCO in the capsulorhexis area.

    2 years after surgery

  • 100% LogMAR Best Corrected Visual Acuity (BCVA)

    Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under high contrast (100%), which means that there was maximum contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better visual acuity.

    24 months after surgery

  • 9% LogMAR Best Corrected Visual Acuity (BCVA)

    Best spectacle corrected vision was recorded for each eye of the patients at above follow up visits. The Visual Acuity (VA) measurement was taken under low contrast (9%), which means that there was low contrast between the letters on the chart and the background. VA is measured in logMAR. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better visual acuity.

    24 months after surgery

Study Arms (2)

SN60AT

EXPERIMENTAL

Implantation with the AcrySof Intraocular Lens Model SN60AT

Device: SN60AT

SN60WF

ACTIVE COMPARATOR

Implantation with the AcrySof Intraocular Lens Model SN60WF

Device: SN60WF

Interventions

SN60ATDEVICE

Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.

SN60AT
SN60WFDEVICE

Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.

SN60WF

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with bilateral senile cataracts
  • Age \> 50 years
  • Fit for hospital follow ups
  • Pupils dilating \> 6mm preoperatively
  • Eyes expected to see 6/12 or better postoperatively

You may not qualify if:

  • Diabetes
  • On treatment for glaucoma
  • Other ocular pathology
  • Previous ocular surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Contact Alcon Call Center for Trial Locations

Fort Worth, Texas, 76134, United States

Location

MeSH Terms

Conditions

Cataract

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Results Point of Contact

Title
Alcon Clinical
Organization
Alcon Research, Ltd.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 26, 2008

First Posted

September 30, 2008

Study Start

December 1, 2006

Primary Completion

August 1, 2009

Last Updated

December 22, 2010

Results First Posted

December 22, 2010

Record last verified: 2010-11

Locations